Cytokinetics' Launch Compounds as ACACIA Opens the Non-Obstructive Door
Q2 dispenses nearly triple to 1,500 patients, new-to-brand exit share tops 40%, and a positive nHCM readout could double the addressable HCM market
CYTK · Earnings Call · 2026-08-06
A Launch That's Compounding
Eight months ago, Cytokinetics was a pre-revenue biotech awaiting an FDA decision on its first drug. Today it is a commercial company whose launch curve is beating its own internal expectations. The launch of MYQORZO has become the narrative centerpiece — and the disclosures this quarter show why the optimism is more than scripted. “Just 5 months into the commercial launch of MYQORZO, we are demonstrating increased velocity that's exceeding expectations.” — Robert I. Blum, President and Chief Executive Officer · 2026-08-06 The clearest evidence is the decision to switch reporting from prescriptions written to prescriptions dispensed — the metric that actually drives revenue. In Q1, ~680 prescriptions translated to ~400 dispenses. By the end of Q2, cumulative dispenses had nearly tripled to 1,500, with ~2,000 prescriptions written; the gap represents patients sitting in the benefits-investigation and prior-auth queue. Andrew Callos explained the mechanics:The quality of demand matters as much as the quantity. New patient starts are broadening beyond the expected centers of excellence: more than 700 unique HCPs wrote prescriptions, half were low-volume or first-time CMI writers, and exit share for MYQORZO in new-to-brand CMI prescriptions exceeded 40% exiting June. Compare this to February, when the drug had been in market just three weeks and Andrew Callos described the onboarding dynamic as frictionless: “The REMS certification... has really not been a barrier to be REMS-certified.” — Andrew M. Callos, Executive Vice President and Chief Commercial Officer · 2026-02-24 That prediction is now visible in a ~30% conversion from REMS-certified HCPs (~2,500) to actual prescribers.You're right, 680 to 400 in Q1 to around 2,000 to 1,500 in Q2, launched to date overall... there is a process, a REMS enrollment has to occur, a prescription has to occur, signatures, both on physician and patient side, benefit investigation, oftentimes prior auths.
ACACIA: The Bigger Prize
The launch is the today story; the non-obstructive HCM (nHCM) opportunity is the tomorrow story. ACACIA-HCM hit both dual primary endpoints — KCCQ Clinical Summary Score and Peak VO2 — in a population with no approved therapy, a result Robert Blum framed as foundational:The results from Acacia HCM get their full airing at ESC later this month, and the company plans to file the nHCM sNDA in Q4. Fady Malik underscored the size of the prize: nHCM “represents as much as 1/2 or more of the overall HCM population” — Fady Malik, Medical Affairs/Clinical Development · 2026-08-06. A successful filing positions aficamten — the aficamten in nHCM story — as potentially the only approved therapy across the HCM spectrum, with a label expansion that could come as early as 2027.These results represent an important scientific achievement for an nHCM patient population with no currently approved therapies and they define a meaningful step toward expanding the potential reach of aficamten beyond oHCM.